Open AccessProlonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis
Author(s) -
Neil J. Mansfield,
Sally Hamour,
A.-M. Habib,
Ruth M. Tarzi,
Jeremy Levy,
Megan Griffith,
Tom Cairns,
H. Terence Cook,
C. D. Pusey,
Alan D. Salama
Publication year - 2011
Publication title -
nephrology dialysis transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.654
H-Index - 168
eISSN - 1460-2385
pISSN - 0931-0509
DOI - 10.1093/ndt/gfr127
Subject(s) - medicine , azathioprine , rituximab , cyclophosphamide , regimen , adverse effect , vasculitis , gastroenterology , surgery , prednisone , malignancy , prednisolone , chemotherapy , disease , lymphoma
Rituximab (RTX) has been shown to be effective as an induction agent in anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV), but studies have been limited by short-term follow-up. We decided to investigate the long-term efficacy and safety of an RTX-based cyclophosphamide (CYP)-sparing regimen (CycLowVas) for renal AAV.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom